AbbVie Buys Drugmaker Shire for 54 Billion

AbbVie Buys Drugmaker Shire for $54 Billion

July 18, 2014
Shire Pharmaceuticals has accepted a $54-billion takeover bid from AbbVie in a deal aimed at slashing the U.S. giant's tax bill.

LONDON -- Shire Pharmaceuticals (IW 1000/802) has accepted a $54-billion takeover bid from AbbVie (IW 500/65) (ABBV), the two companies announced Friday, in a deal aimed at slashing the U.S. giant's tax bill.

The takeover, priced with a 53% premium for Shire stock, comes after Ireland-based Shire reversed its opposition to a deal earlier this week.

"The boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie," the two firms said in a statement.

The offer, comprising £24.44 in cash and 0.8960 AbbVie share per Shire share, is the same as the proposal received by the group last Sunday.

The global pharmaceuticals sector has witnessed a stream of multibillion-dollar deals in recent months, as U.S. companies look to Europe as a way to minimize their tax liabilities.

In late May, Anglo-Swedish group AstraZeneca (IW 1000/157) fought off a $117 billion takeover bid from U.S. giant Pfizer (IW 500/25) (PFE) amid worries over British jobs and research capability.

There were also accusations that the tie-up was a cynical ploy by Pfizer to avoid paying tax on profits if they were sent to the United States. The U.S. group had also proposed to switch its tax base to Britain from the U.S.

By Roland Jackson

Copyright Agence France-Presse, 2014

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!